SCHEMBL23833590

SCHEMBL23833590

Cc1cc(NN)ncc1NS(C)(=O)=O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PIK3CB P42338 3/20 0.41
▸ PIK3CA P42336 3/20 0.41
▸ PIK3CD O00329 2/20 0.41
▸ PIK3CG P48736 2/20 0.41
▸ KEAP1 Q14145 1/20 0.39
▸ NFE2L2 Q16236 1/20 0.39
▸ PTGS1 P23219 3/20 0.38
▸ PTGS2 P35354 2/20 0.38
▸ BACE1 P56817 2/20 0.36
▸ ABL1 P00519 1/20 0.36
▸ PIK3C3 Q8NEB9 1/20 0.36
▸ KDM4E B2RXH2 3/20 0.36
▸ GAA P10253 3/20 0.36
▸ MAPT P10636 3/20 0.36
▸ CCNT1 O60563 1/20 0.35
▸ CDK9 P50750 1/20 0.35
▸ TNIK Q9UKE5 1/20 0.35
▸ NNMT P40261 1/20 0.35
▸ ALDH1A1 P00352 1/20 0.35
▸ MEN1 O00255 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30094536 1.00 PIK3CB (0.41) PIK3CBPIK3CAPIK3CDPIK3CGKEAP1
SCHEMBL30094638 0.76 L3MBTL1 (0.42) PIK3C3KDM4EGAAMAPTNNMT
SCHEMBL23833547 0.76 L3MBTL1 (0.42) PIK3C3KDM4EGAAMAPTNNMT
SCHEMBL30094525 0.76 PIK3CA (0.46) PIK3CBPIK3CAPIK3CDPIK3CGKEAP1
SCHEMBL23833571 0.76 PIK3CA (0.46) PIK3CBPIK3CAPIK3CDPIK3CGKEAP1
SCHEMBL16492684 0.76 KEAP1 (0.41) PIK3CBPIK3CAPIK3CDPIK3CGKEAP1
SCHEMBL1284798 0.74 PIK3CB (0.39) PIK3CBPIK3CAPIK3CDPIK3CGKEAP1
SCHEMBL25518454 0.73 CDK1 (0.37) KDM4EGAAMAPTNNMTALDH1A1
SCHEMBL16492683 0.73 TNIK (0.47) PIK3CBPIK3CAPIK3CDPIK3CGKEAP1
SCHEMBL23845561 0.72 NNMT (0.33) NNMTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230159489-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND USE AKEBIA THERAPEUTICS, INC. (US) 2023-05-25 — — US disclosed
US-20230159489-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND USE AKEBIA THERAPEUTICS, INC. (US) 2023-05-25 — — US disclosed
EP-4121426-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND USE Akebia Therapeutics Inc. (US) 2023-01-25 — — EP disclosed
CN-115515948-A PHD inhibitor compounds, compositions and uses 阿克比治疗有限公司 2022-12-23 — — CN disclosed
WO-2021188938-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND USE AKEBIA THERAPEUTICS, INC. (US) 2021-09-23 — — WO disclosed
WO-2021188938-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND USE AKEBIA THERAPEUTICS, INC. (US) 2021-09-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230159489-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND USE HIF1AN, EGLN3, PHF20 PIK3CB 2411/4885PIK3CA 2114/4885PIK3CD 2134/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback